The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Relmada expects to initiate its Phase 3 program in the first half of 2026
Venus Remedies now has 29 active product approvals in Vietnam alone
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Poviztra is a second brand of Wegovy
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
Subscribe To Our Newsletter & Stay Updated
